Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

FDA approves Atellica IM free PSA II to help separate prostate cancer from benign disease

On May 11, 2026, the FDA approved the Atellica IM free PSA II assay to measure free PSA with a total PSA assay in men 50 years and older whose total PSA is 4 to 10 ng/mL and whose digital rectal exam is not suspicious for cancer, as an aid in distinguishing prostate cancer from benign prostatic disease.

U.S. FDA